{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:59:59Z","timestamp":1778867999411,"version":"3.51.4"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0037019","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T21:14:51Z","timestamp":1337289291000},"page":"e37019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates"],"prefix":"10.1371","volume":"7","author":[{"given":"Jing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Tricoche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaddam","family":"Goud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth S.","family":"Didier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston A.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lustigman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm0411-415","article-title":"Alum&apos;s adjuvant action: grease is the word.","volume":"17","author":"ML Mbow","year":"2011","journal-title":"Nat Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nm.2306","article-title":"Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity.","volume":"17","author":"TL Flach","year":"2011","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination.","volume":"12","author":"B Pulendran","year":"2011","journal-title":"Nat Immunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work.","volume":"33","author":"RL Coffman","year":"2010","journal-title":"Immunity"},{"key":"ref5","first-page":"250","article-title":"Adjuvants for the future.","author":"RT Kenney","year":"2010"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1016104910582","article-title":"Recent advances in vaccine adjuvants.","volume":"19","author":"M Singh","year":"2002","journal-title":"Pharm Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.2741\/2887","article-title":"Rationally-designed vaccine adjuvants: separating efficacy from toxicity.","volume":"13","author":"TM Hauguel","year":"2008","journal-title":"Front Biosci"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e1001147","DOI":"10.1371\/journal.ppat.1001147","article-title":"Enhancing oral vaccine potency by targeting intestinal M cells.","volume":"6","author":"A Azizi","year":"2010","journal-title":"PLoS Pathog"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri2992","article-title":"Diversity and dialogue in immunity to helminths.","volume":"11","author":"JE Allen","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nri1183","article-title":"Immune regulation by helminth parasites: cellular and molecular mechanisms.","volume":"3","author":"RM Maizels","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1471-4892(03)00077-8","article-title":"T helper type-2 cytokine responses: potential therapeutic targets.","volume":"3","author":"AG Jarnicki","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.4049\/jimmunol.173.12.7454","article-title":"Helminth antigens modulate TLR-initiated dendritic cell activation.","volume":"173","author":"CM Kane","year":"2004","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1126\/science.1109893","article-title":"TLR11 activation of dendritic cells by a protozoan profilin-like protein.","volume":"308","author":"F Yarovinsky","year":"2005","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1016\/j.vaccine.2005.01.098","article-title":"rOv-ASP-1, a recombinant secreted protein of the helminth <italic>Onchocerca volvulus<\/italic>, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.","volume":"23","author":"AJ MacDonald","year":"2005","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0020-7519(01)00213-2","article-title":"Immune evasion genes from filarial nematodes.","volume":"31","author":"RM Maizels","year":"2001","journal-title":"Int J Parasitol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.0105-2896.2004.00191.x","article-title":"Helminth parasites\u2013masters of regulation.","volume":"201","author":"RM Maizels","year":"2004","journal-title":"Immunol Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.4049\/jimmunol.171.4.2127","article-title":"A novel therapeutic approach targeting articular inflammation using the filarial nematode-derived phosphorylcholine-containing glycoprotein ES-62.","volume":"171","author":"IB McInnes","year":"2003","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.imlet.2004.04.008","article-title":"ES-62, a filarial nematode-derived immunomodulator with anti-inflammatory potential.","volume":"94","author":"W Harnett","year":"2004","journal-title":"Immunol Lett"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/IAI.70.11.6058-6067.2002","article-title":"Modulation of a heterologous immune response by the products of <italic>Ascaris suum<\/italic>.","volume":"70","author":"JC Paterson","year":"2002","journal-title":"Infect Immun"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.molimm.2004.03.020","article-title":"<italic>Taenia crassiceps<\/italic> carbohydrates stimulate IL-6 expression in naive murine macrophages via Toll-like receptors (TLRs).","volume":"41","author":"S Dissanayake","year":"2004","journal-title":"Mol Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"48122","DOI":"10.1074\/jbc.M206941200","article-title":"A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization.","volume":"277","author":"D van der Kleij","year":"2002","journal-title":"J Biol Chem"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1521-4141(200007)30:7<1977::AID-IMMU1977>3.0.CO;2-3","article-title":"Proteins secreted by the parasitic nematode <italic>Nippostrongylus brasiliensis<\/italic> act as adjuvants for Th2 responses.","volume":"30","author":"MJ Holland","year":"2000","journal-title":"Eur J Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1002\/eji.200425167","article-title":"Selective maturation of dendritic cells by <italic>Nippostrongylus brasiliensis<\/italic>-secreted proteins drives Th2 immune responses.","volume":"34","author":"A Balic","year":"2004","journal-title":"Eur J Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4049\/jimmunol.167.1.442","article-title":"Lacto-N-fucopentaose III found on <italic>Schistosoma mansoni<\/italic> egg antigens functions as adjuvant for proteins by inducing Th2-type response.","volume":"167","author":"M Okano","year":"2001","journal-title":"J Immunol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.4049\/jimmunol.171.11.5837","article-title":"Maturation of dendritic cell 2 phenotype by a helminth glycan uses a toll-like receptor 4-dependent mechanism.","volume":"171","author":"PG Thomas","year":"2003","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.vaccine.2005.09.014","article-title":"A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine.","volume":"24","author":"R Segura-Velazquez","year":"2006","journal-title":"Vaccine"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.4049\/jimmunol.0800531","article-title":"Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth <italic>Onchocerca volvulus<\/italic>, can directly bind and activate antigen-presenting cells.","volume":"182","author":"Y He","year":"2009","journal-title":"J Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1016\/j.vaccine.2010.08.049","article-title":"Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to <italic>Onchocerca volvulus<\/italic> activation associated protein-1 (ASP-1) adjuvant.","volume":"28","author":"G Zhao","year":"2010","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1016\/j.vaccine.2008.07.028","article-title":"Evaluation of recombinant <italic>Onchocerca volvulus<\/italic> activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.","volume":"26","author":"W Xiao","year":"2008","journal-title":"Vaccine"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2249.2008.03623.x","article-title":"A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.","volume":"152","author":"AJ MacDonald","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.vaccine.2008.01.025","article-title":"Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.","volume":"26","author":"L Du","year":"2008","journal-title":"Vaccine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.4049\/jimmunol.180.2.948","article-title":"Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.","volume":"180","author":"L Du","year":"2008","journal-title":"J Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.4049\/jimmunol.177.12.8531","article-title":"Local and systemic effects of intranodally injected CpG-C immunostimulatory-oligodeoxyribonucleotides in macaques.","volume":"177","author":"N Teleshova","year":"2006","journal-title":"J Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1189\/jlb.0205084","article-title":"CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.","volume":"79","author":"N Teleshova","year":"2006","journal-title":"J Leukoc Biol"},{"key":"ref35","first-page":"w13108","article-title":"Anti-cytokine vaccination in autoimmune diseases.","volume":"140","author":"L Delavallee","year":"2010","journal-title":"Swiss Med Wkly"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00005-011-0129-y","article-title":"Cancer vaccines. Any future?","volume":"59","author":"LA Myc","year":"2011","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants.","volume":"10","author":"VE Schijns","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4049\/jimmunol.0902539","article-title":"Recent developments in cancer vaccines.","volume":"186","author":"K Palucka","year":"2011","journal-title":"J Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0264-410X(96)00183-1","article-title":"Adjuvants\u2013a classification and review of their modes of action.","volume":"15","author":"JC Cox","year":"1997","journal-title":"Vaccine"},{"key":"ref40","first-page":"469","article-title":"Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.","author":"S Benko","year":"2008"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1006\/cimm.2000.1689","article-title":"Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.","volume":"204","author":"JP Vasilakos","year":"2000","journal-title":"Cell Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants.","volume":"11","author":"A Pashine","year":"2005","journal-title":"Nat Med"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.vaccine.2006.08.013","article-title":"Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity.","volume":"25","author":"JW Huleatt","year":"2007","journal-title":"Vaccine"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1086\/517613","article-title":"A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity.","volume":"195","author":"WF McDonald","year":"2007","journal-title":"J Infect Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/14760584.6.5.673","article-title":"The science of adjuvants.","volume":"6","author":"M Kwissa","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.","volume":"8","author":"DJ Marciani","year":"2003","journal-title":"Drug Discov Today"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants\u2013in retrospect and prospect.","volume":"22","author":"EB Lindblad","year":"2004","journal-title":"Vaccine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0959-8049(02)00479-3","article-title":"Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.","volume":"39","author":"M Marchand","year":"2003","journal-title":"Eur J Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2007.10.062","article-title":"Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.","volume":"26","author":"JW Huleatt","year":"2008","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/S0264-410X(02)00413-9","article-title":"Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers.","volume":"20","author":"L Vernacchio","year":"2002","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1016\/S0264-410X(01)00142-6","article-title":"Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21.","volume":"19","author":"DC Waite","year":"2001","journal-title":"Vaccine"},{"key":"ref52","first-page":"870","article-title":"CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.","volume":"160","author":"HL Davis","year":"1998","journal-title":"J Immunol"},{"key":"ref53","first-page":"3942","article-title":"Adjuvant-guided type-1 and type-2 immunity: infectious\/noninfectious dichotomy defines the class of response.","volume":"162","author":"HC Yip","year":"1999","journal-title":"J Immunol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1034\/j.1600-0625.2002.110204.x","article-title":"Induction of skewed Th1\/Th2 T-cell differentiation via subcutaneous immunization with Freund&apos;s adjuvant.","volume":"11","author":"A Shibaki","year":"2002","journal-title":"Exp Dermatol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.","volume":"15","author":"DH Cribbs","year":"2003","journal-title":"Int Immunol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.vaccine.2006.10.031","article-title":"Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.","volume":"25","author":"L Du","year":"2007","journal-title":"Vaccine"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1128\/IAI.73.10.6903-6911.2005","article-title":"Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm <italic>Ancylostoma caninum<\/italic>.","volume":"73","author":"B Zhan","year":"2005","journal-title":"Infect Immun"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1016\/j.vaccine.2005.04.040","article-title":"Expression of the <italic>Necator americanus<\/italic> hookworm larval antigen Na-ASP-2 in <italic>Pichia pastoris<\/italic> and purification of the recombinant protein for use in human clinical trials.","volume":"23","author":"GN Goud","year":"2005","journal-title":"Vaccine"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.virol.2009.07.018","article-title":"Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.","volume":"393","author":"L Du","year":"2009","journal-title":"Virology"},{"key":"ref60","article-title":"Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.","author":"L Du","year":"2011"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/vim.2009.0090","article-title":"A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.","volume":"23","author":"L Du","year":"2010","journal-title":"Viral Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0037019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T08:12:17Z","timestamp":1589011937000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0037019"}},"subtitle":[],"editor":[{"given":"Kevin K. A.","family":"Tetteh","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2012,5,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0037019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}